Pfizer Inc (PFE)
Health Care · Pharmaceuticals · US stock · S&P 500 component
$29.58
▲ +0.14 (0.48%)
Fair valueOvervalued
$16 −46.7% to fair value
$8fair band $9–$22$24
Day's range
$29.42 – $29.74
52-week range
$22.57 – $29.88
About Pfizer Inc
Pfizer is a global biopharmaceutical company that discovers, develops and supplies medicines and vaccines. Its portfolio includes the pneumococcal vaccine Prevnar, the blood thinner Eliquis, the cancer medicine Ibrance and a COVID vaccine and antiviral treatment, plus products in inflammation and rare disease. It also added cancer medicines through its purchase of Seagen. Customers are wholesalers, hospitals, pharmacies and governments.
Revenue of $63.7 billion over the last twelve months comes from patented medicines and vaccines. Revenue has changed at -14.8% a year across the last three years, a sharp decline. The operating margin is 10.8%, the business earns 4% on the capital invested in it, and net debt is 4.1 times EBITDA. The dividend yield is 5.8%. On the site's X-Ray Score it receives 27 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $22.57 – $29.88Volume 28,612,900Daily, split-adjusted
Vitals
Market cap$168.6B
52-week range$22.57 – $29.88
Volume (last day)28,612,900
P/E (TTM)39.0
EBIT / EV yield3.1%
Free-cash-flow yield6.5%
Dividend yield5.8%
Revenue (TTM)$63.7B
Net income (TTM)$4.3B
Operating margin10.8%
Return on capital4.4%
Debt incl. leases$63.1B
Cash & securities$8.3B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$16model spread $15 – $17
Overvalued
−46.7% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is High, so the safety margin is 40%.
Price $30
Undervalued < $9Fair $9 – $22Overvalued > $22
10-year DCF (market-scaled)
$10
Peer multiples
$21
Earnings power floor (not blended)
$14
Fundamentals-adjusted multiple
$17
Growth the price implies
22.3%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Weak business, priced high
Our models put fair value below today's price, so a lot of good news may already be in the price. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Weak
37/100
Expensive against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield3.1%
Free-cash-flow yield6.5%
Fair value vs price0.5×
Growth
Weak
4/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)-14.8%
EPS growth (3y)-37.1%
Growth consistency60%
Profitability
Weak
30/100
Earns lower returns on its capital than most peers.
See the numbers →
Return on invested capital4.4%
Operating margin10.8%
Gross profitability23.2%
Financial health
Weak
24/100
Balance sheet is more stretched than most peers.
See the numbers →
Piotroski F-Score5 / 9
Net debt / EBITDA4.1×
Interest cover2.6×
Dividends
Fair
50/100
Dividend is typical for its sector.
See the numbers →
Dividend yield5.8%
Dividends vs free cash flow89%
Dividend growth2.8%
Quarterly results: last 6 quarters
-7.8%
Mar '25
+10.3%
Jun '25
-5.9%
Sep '25
-1.2%
Dec '25
+5.4%
Mar '26
+2.6%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $15.0B, diluted EPS $-0.04.
Compare with peers
ZTS Zoetis Inc.68 LLY ELI LILLY & Co61 BMY Bristol Myers Squibb C...59 JNJ Johnson & Johnson50Other Pharmaceuticals companies by X-Ray Score.
Fundamentals checklist
● 2 Good · ● 2 Average · ● 12 BadCash quality
Earnings backed by cashGood
Free-cash-flow yieldGood
Risk models
Altman Z''Average
Piotroski F-ScoreBad
Growth
EPS growth (3y)Bad
Free-cash-flow growth (3y)Bad
Revenue growth (3y)Bad
Growth consistencyBad
Balance sheet
Current ratioAverage
Net debt / EBITDABad
Interest coverBad
Valuation
Fair value vs priceBad
EBIT / EV yieldBad
Profitability
Return on invested capitalBad
Operating marginBad
Gross profitabilityBad
Each check is graded against the company's sector, not a fixed number. Checklist score 27/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $81.3B | $101.2B | $59.6B | $63.6B | $62.6B |
| Operating income | $25.6B | $36.0B | $3.3B | $11.1B | $10.2B |
| Net income | $22.0B | $31.4B | $2.1B | $8.0B | $7.8B |
| Operating cash flow | $32.6B | $29.3B | $8.7B | $12.7B | $11.7B |
| Operating margin | 31.5% | 35.5% | 5.5% | 17.5% | 16.3% |
| Free cash flow | $29.9B | $26.0B | $4.8B | $9.8B | $9.1B |
| Diluted EPS | $3.85 | $5.47 | $0.37 | $1.41 | $1.36 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
12 bullish · 1 neutral · 3 bearish
Weekly
Strongly bullish
11 bullish · 1 neutral · 0 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
| SMA 10 | 28.40 | Bullish |
| EMA 10 | 28.72 | Bullish |
| SMA 20 | 28.34 | Bullish |
| EMA 20 | 28.41 | Bullish |
| SMA 50 | 27.97 | Bullish |
| EMA 50 | 27.74 | Bullish |
| SMA 100 | 26.34 | Bullish |
| EMA 100 | 26.95 | Bullish |
| SMA 200 | 26.03 | Bullish |
| EMA 200 | 26.08 | Bullish |
Oscillators (daily)
| RSI (14) | 69.81 | Neutral |
| MACD (12, 26) | 0.36 | Bullish |
| Momentum (12) | 3.72 | Bullish |
| Stochastic %K (14) | 89.13 | Bearish |
| Williams %R (14) | -10.87 | Bearish |
| CCI (20) | 176.2 | Bearish |
Pivot points (classic, last session)
S3 29.10 | S2 29.26 | S1 29.42 | Pivot 29.58 | R1 29.74 | R2 29.90 | R3 30.06 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
1.72 USD
Yield on today's price
5.81%
Frequency
Quarterly
Next ex-dividend date
6 Nov 2026
| Ex-dividend date | Amount per share |
|---|---|
| 6 Nov 2026 (upcoming) | 0.4300 |
| 24 Jul 2026 | 0.4300 |
| 8 May 2026 | 0.4300 |
| 23 Jan 2026 | 0.4300 |
| 7 Nov 2025 | 0.4300 |
| 25 Jul 2025 | 0.4300 |
| 9 May 2025 | 0.4300 |
| 24 Jan 2025 | 0.4300 |
| 8 Nov 2024 | 0.4200 |
| 26 Jul 2024 | 0.4200 |
| 9 May 2024 | 0.4200 |
| 25 Jan 2024 | 0.4200 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
PFE SEC filings
4 Aug 2026
10-QSEC EDGAR
Quarterly report
4 Aug 2026
8-KSEC EDGAR
Results of operations
18 Jun 2026
8-KSEC EDGAR
Regulation FD disclosure
18 Jun 2026
8-KSEC EDGAR
Director or officer change
5 May 2026
10-QSEC EDGAR
Quarterly report
5 May 2026
8-KSEC EDGAR
Results of operations
27 Apr 2026
8-KSEC EDGAR
Shareholder vote results
12 Mar 2026
DEF 14ASEC EDGAR
Proxy statement
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.